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use of LC instead of GC is justified by the growing implementation of LC for the study of β2-
agonists, since this technique does not require previous derivatization steps. Although these ideas 
are spread along the manuscripts, a deeper discussion of the advantages of this method compared 
to other commonly used methods would be very useful for the reader. This could be done in an 
additional section between current sections 3.2 and 3.3. In this section, specific points such as the 
time for sample preparation, use of reagents, sensitivity or selectivity could be discussed. A new 3.3 
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reviewed. 
• Highlights: Please, highlight that the method has been validated according to ISO 17025:2005 
principles. This is the main point in this work. A new highlight was added.
• Abbreviations: Avoid defining abbreviations that are standard in the journal: 
https://www.elsevier.com/__data/promis_misc/JPBA%20Abbreviations.pdf Many defining 
abbreviations were removed (lines 34, 68, 73, 74, 76, 77, 87, 153, 155, 162, 186, 187, 193, 293).
• Line 65. “These methods are…” The change was made.
• Line 162. I guess these individuals were not in any treatment with β2-agonists. Please, specify what 
the term "blank" means. The text “not in therapy with β2-agonists” was added. 
• Line 186. “With respect to the RSD” The change was made.
REVIEWER 2
The manuscript deals with the development of a development of an UHPLC-MS/MS method for beta2-
agonists determination in human urine samples.
The paper is well written and organized. The validation procedure is precisely carried out and the topic of 
the paper is worthy of publication in the JPBA after some revisions of the text. 
Comments:
-Title: beta2-agonists were quantified in urine human samples and not only detected. I suggest to change 
the title in turn. The change was made.
- L134-136. I don't understand why the eluate was reconstituted with a mixture 95/5 metanol/water, 
instead of a mixture 95/5 water/methanol, i.e. the initial gradient composition of the mobile phase. This is 
enough strange. Yes, it was wrong. It was a typographical error. The right percentage was replaced. 
- L141. Modify "BEH C18 column (2.1 mm x 100 mm, 1.8 um)" and specify the geometry of the pre-column 
too. The change was made.
-L146. delete "Sciex", since already afterward reported. The change was made.
- L 264. Did the authors use weighting factors for calibration plots? No, we did not. 
- L359, 382  Add the standard deviation. Media value and standard deviation was added. In L359 also a 
typographical error was correct: as reported in Table 5 for patients under acute therapy with formoterol, all 
the detected concentrations were lower than 2.0 ng/mL and not 0.70 ng/mL.
- L 374, 379. Change "ppb" in appropriate concentration unit. The change was made.
- Table 1. Column 6. Change "target fragment" with " Quantifier fragment" for analogy with column 9. The 
change was made.
- Table 2. The linearity range reported in this table are not correct. The lowest value of the linearity range 
must be always the LOQ value! The change was made.
- Table 2. In this table, the LOD values are the same of LOQ values for 3 analytes (clencicloexerol, 
hydroxymethylclebuterol and salmeterol). Although the authors use the Hubaux-Vox method for the 
calculation of LODs and LOQs, I ask them to justify these values, as the meaning of LOD and LOQ are 
different, and if LOD = LOQ an explanation in the text must be given. LOD and LOQ appeared to be the 
same for these analytes because of the approximation to a single significant digit. By adding a decimal digit, 
as in the new Table 2, different and more correct expression of LOD and LOQ is obtained.
- Caption of figure 3. Please check the significant digits and add the standard deviations. Significant digits 
were checked and standard deviations were added. 
- Figures 2 and 3. Show both the quantifier and qualifier transitions for each chromatographic peak. The 
qualifier fragments were added in both figures. The text “In black is reported the quantifier fragment and in 
red the qualifier fragment.” was added in the figure captions.
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 A UHPLC-MS/MS method was developed for the detection of 24 β2-agonists in urine
 The method was fully validated according to UNI EN ISO IEC 17025:2005
 The suitability of the method was proved by real samples testing
 The β2-agonists urinary concentration varies with administered dose and duration
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30 A fast analytical method for the simultaneous detection of 24 β2-agonists in human urine was 
31 developed and validated. The method covers the therapeutic drugs most commonly administered, 
32 but also potentially abused β2-agonists. The procedure is based on enzymatic deconjugation with 
33 β-glucuronidase followed by SPE clean up using mixed-phase cartridges with both ion-exchange 
34 and lipophilic properties. Instrumental analysis conducted by ultra-high performance liquid 
35 chromatography–tandem mass spectrometry (UHPLC–MS/MS) allowed high peak resolution and 
36 rapid chromatographic separation, with reduced time and costs. The method was fully validated 
37 according ISO 17025:2005 principles. The following parameters were determined for each analyte: 
38 specificity, selectivity, linearity, limit of detection, limit of quantification, precision, accuracy, 
39 matrix effect, recovery and carry-over. The method was tested on real samples obtained from 
40 patients subjected to clinical treatment under chronic or acute therapy with either formoterol, 
41 indacaterol, salbutamol, or salmeterol. The drugs were administered using pressurized metered 
42 dose inhalers. All β2-agonists administered to the patients were detected in the real samples. The 
43 method proved adequate to accurately measure the concentration of these analytes in the real 
44 samples. The observed analytical data are discussed with reference to the administered dose and 




48 β-adrenergic agonists, or β2-agonists, are among the oldest and most commonly prescribed 
49 therapeutic agents for the treatment of asthma, a chronic inflammatory airway disorder. β2-
50 agonists are widely used also to treat chronic obstructive pulmonary disease (COPD) and 
51 numerous other respiratory diseases, either alone or in combination with bronchodilators and 
52 corticosteroids [1]. From the chemical point of view, β2-agonists are phenyl β2-ethanolamines 
53 bearing different substituents on the amino- nitrogen and the phenylic ring, with chemical 
54 structures closely related to endogenous catecholamines [2]. 
55 Because of their therapeutic stimulatory effect on the breath capacity and central nervous system, 
56 β2-agonists are occasionally abused by chronic asthmatic patients, possibly leading to severe 
57 intoxication. They are also misused in sport and animal husbandry as growth promoters, due to 
58 their side effects on protein synthesis and lipolysis, that depend on the dose and administration 
59 route, possibly resulting in an anabolic-like action [3]. For these reasons, the identification and 
60 quantification of β2-agonists in various biological matrices is important, and requires selective and 
61 sensitive analytical methods. 
62 Among the biological matrices, urine presents many advantages for drugs detection. Unlike blood, 
63 urine sampling is non-invasive and naturally produce a larger volume. In urine, β2-agonists are 
64 typically excreted as either phase I or phase II metabolites, accompanied by a large percentage of 
65 the unmodified drug, depending on the dose and administration route. This allows to explore a 
66 wider temporal window after the last assumption, extending to a few days.
67 Laboratory methods for β2-agonists are commonly based on a chromatographic technique coupled 
68 with mass spectrometry (MS), which undoubtedly offers great performances for complex mixture 
69 analysis, in terms of analytical sensitivity and specificity, detection limits and quantitation 
70 capabilities [4]. These methods are required for confirmation purposes in official zootechnics 
71 controls [5], but they can also be used as screening methods, since they generally provide the 
72 required sensitivity for a wide range of analytes, together with qualitative and quantitative 
73 information [6]. Gas chromatography MS (GC-MS) methods had been initially reported for β2-
74 agonist analysis [7,8], but they were subsequently replaced by LC-MS liquid chromatography – 
75 mass spectrometry methods (LC-MS) that require no derivatization steps, and allow higher 
76 sensitivity and specificity by means of MS/MS tandem MS conditions (MS/MS) [9,10]. 
77 Recent efforts were made to develop analytical methods based on ultra-high performance liquid 
78 chromatography (UHPLC)- MS/MS to obtain high peak resolution, high sensitivity, rapid 
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79 chromatographic separation, and reduced analysis time and costs at the same time. To date, only 
80 few UHPLC methods have been described to detect simultaneously a large set for β2-agonists. 
81 Multi-target methods were developed respectively for 18 β2-agonists detection in bovine urine 
82 [11], 20 β2-agonists in bovine hair [12], 16 β2-agonists in pig liver, kidney and muscle [13], and 11 
83 β2-agonists in human urine [14]. The latter method reported homogeneous LOD values of 0.1 
84 ng/mL for all targeted analytes, including salmeterol, whose actual concentration in urine after 
85 clinical administration is frequently below this 0.1 ng/mL limit [15]. 
86 To improve sensitivity toward β2-agonists, several clean-up procedures have been proposed 
87 before instrumental detection. Most clean-up methods were based on solid phase extraction (SPE) 
88 using different sorbents [16,17], but also other techniques such as matrix solid phase dispersion 
89 [18], immunoaffinity based techniques [19] and supercritical fluids extraction [20] have been 
90 reported. Lately, molecularly imprinted polymer technology [21,22] has also been experimentally 
91 applied to the clean-up of β2-agonists. 
92 Until recently, our laboratory used a fast-GC-MS method for the simultaneous determination of 15 
93 2-agonists in human urine [23]. The need to improve further the sample throughput and general 
94 applicability made us develop a new sensitive and robust UHPLC-MS/MS method for the detection 
95 of 24 β2-agonists (Figure 1) in human urine, covering the therapeutic drugs most commonly 
96 administered, but also potentially abused β2-agonists and “cocktails”, i.e. mixtures of β2-agonists 
97 with or without other anabolic substances [24]. The present method was validated in agreement 
98 with the UNI EN ISO IEC 17025:2005 [25] principles and successfully applied to the therapeutic 
99 monitoring of patients with respiratory-related diseases, after their treatment with various β2-
100 agonists.
101
102 2. Material and methods
103 2.1. Reagent and chemicals
104 Bambuterol hydrochloride, bromchlorbuterol hydrochloride, brombuterol hydrochloride, 
105 cimaterol, cimbuterol, clenbuterol hydrochloride, clecicloexerol hydrochloride, clenpenterol 
106 hydrochloride, clenproperol, fenoterol hydrobromide, formoterol fumarate dihydrate,  
107 hydroxymethylclenbuterol, isoxsuprine hydrochloride, mabuterol hydrochloride, mapenterol 
108 hydrochloride, procaterol hydrochloride, ractopamine hydrochloride, ritodrine hydrochloride, 
109 salbutamol, terbutaline sulfate, tulobuterol hydrochloride, methanol, formic acid (LC-MS Ultra 
110 grade, ~98%), ammonium acetate, β-glucuronidase type II from helix pomatia, and ammonium 
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111 hydroxide were purchased from Sigma-Aldrich (St. Louis, MO, USA). Indacaterol and formoterol-
112 13C-d3 were purchased from AlsaChim (Illkirch Graffenstaden, France). Salmeterol xinafoate was 
113 supplied by the European Directorate for the Quality of Medicines & HealthCare (, Strasbourg, 
114 France). Zilpaterol was obtained from Spectra 2000 srl (Rome, Italy). Clenbuterol-d6 was supplied 
115 by the Netherlands National Institute for Public Health and the Environment (RIVM, Bilthoven, 
116 Netherlands). Salbutamol-d3 was purchased from LGC (Teddington, Middlesex, United Kingdom), 
117 salmeterol-d3 from CDN Isotope (Pointe-Claire, Quebec, Canada). Hydrochloric acid (HCl) 37% was 
118 purchased from Carlo Erba (Milan, Italy). Ultrapure water was obtained using a Milli-Q® UF 
119 apparatus (Millipore, Bedford, MA, USA). 
120 All stock standard solutions were prepared in methanol at 1 mg/mL and stored at 20° C in the 
121 dark until use. Working solutions were prepared by dilution with methanol. 
122 Four deuterated internal standards (salbutamol-d3, clenbuterol-d6, formoterol-13C-d3, and 
123 salmeterol-d3) were used for the quantitation procedure at equal concentration. Blank urine 
124 samples were collected from healthy volunteers (laboratory personnel), pooled, and used as the 
125 working matrix to develop and validate the analytical protocol. 
126
127 2.2. Sample preparation
128 An aliquot (3 mL) of urine specimen was centrifuged at 3500 rpm for 5 min. Subsequently, 2.5 mL 
129 of supernatant was transferred into 30-mL glass tubes and 25 µL of the internal standard (IS) 
130 solution (concentration of 0.1 µg/mL) was added. A 0.2 M aqueous ammonium acetate solution at 
131 pH 5.0 was added (2.5 mL) into the samples, together with 10 µL of β-glucuronidase. Enzymatic 
132 deconjugation was carried out for 2 h at 37° C. The samples were allowed to cool down to room 
133 temperature and then loaded onto a SPE Strata-XC 33 µm, 60 mg x 3 mL cation exchange cartridge 
134 (Phenomenex, Castel Maggiore (BO), Italy), previously conditioned with 2 mL of methanol and 2 
135 mL of ultrapure water. After sample loading, the SPE cartridges were washed with 2 mL HCl 0.1 M 
136 and then 2 mL of methanol. The target analytes were eluted with 2 mL of methanol doped with 5% 
137 (v/v) of ammonium hydroxide. The eluate was evaporated to dryness under a gentle stream of 
138 nitrogen and at 50° C using a Techne Sample Concentrator (Barloworld Scientific, Stone, UK), and 
139 then reconstituted with 100 µL of a methanol-0.1% formic acid aqueous solution (95:95, v/v) and 
140 transferred into the analytical vial for UHPLC-MS/MS analysis. 
141
142 2.3. UHPLC-MS/MS analysis
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143 Chromatographic separations were performed on an Agilent Infinity 1290 UHPLC system (Agilent 
144 Technologies, Palo Alto, CA, USA), including a vacuum degasser, a binary pump, an autosampler 
145 and a column thermostat. The liquid chromatograph was equipped with a Waters (Milford, MA, 
146 USA) BEH C18 column – (2.1 mm x 100 mm x 1.8 7 µm) column maintained at 40°C and a n 
147 analogueWaters (Milford, MA, USA) BEH C18 vanguard pre-column (2.1 mm x 5 mm x 1.7 µm). The 
148 chromatographic run was carried out by a binary mobile phase of a 0.1% v/v aqueous formic acid 
149 solution and methanol, using the following program: isocratic with 5% methanol for 2 min; linear 
150 gradient from 5% to 80% in 8 min; isocratic with 80% methanol for 1 min; total run time 15 min. 
151 The injection volume was 1 µL and the flow-rate was 0.4 mL min−1. The LC was interfaced to a 
152 Sciex QTRAP® 4500 triple–quadrupole mass spectrometer (Sciex, Ontario, Canada), operating in 
153 electrospray ionization (ESI) – positive ion mode. The other MS parameters were set as follows: 
154 curtain gas: 35 psi; nebulizer gas: 45 psi; heater gas: 40 psi; probe temperature: 550 ◦C; IS voltage: 
155 +3500 V. Ion acquisition was operated at unit mass resolution in the selected reaction monitoring 
156 (SRM) mode, using the two transitions from the protonated molecular ion of each analyte to the 
157 fragment ions indicated in Table 1.
158
159 2.4. Validation
160 The analytical method was validated in accordance with the criteria and recommendations of UNI 
161 EN ISO/IEC 17025:2005 international standard [25]. The following parameters were investigated: 
162 specificity, selectivity, linearity range, detection and quantification limits (LOD and LOQ), intra-
163 assay precision and accuracy. Carry-over, recovery and matrix effect were also investigated. Blank 
164 human urine samples obtained from healthy volunteers were used for the validation experiments 
165 following the analytical protocol described above. 
166
167 2.4.1. Specificity and Selectivity
168 Ten blank urine samples from different individuals not in therapy with β2-agonists  were analysed. 
169 The occurrence of possible interferences from endogenous substances was tested by monitoring 
170 the SRM chromatograms characteristic for each investigated compound at the expected retention 
171 time interval. The signal-to-noise ratio (S/N) was measured on the least intense mass transition at 
172 the expected retention time. The noise was measured from the end of the peak till 0.05 min after 
173 it. A S/N<3 was considered satisfactory in order to verify the method specificity.
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174 Identification criteria for the analytes were established according to Decision 2002/657/EC [5]. For 
175 each analyte, one qualifying mass transition was monitored, in addition to the primary 
176 fragmentation (Table 1). Variations of relative peak intensities were tested at three concentration 
177 levels (concentration of first, third and fifth point of the calibration curves). Retention time (tR) 
178 precision was also tested at the same concentrations.
179
180 2.4.2. Linearity, LOD and LOQ
181 The linear calibration model was checked by analyzing (five replicates) blank urine samples spiked 
182 with the working solution at six concentration levels (see Table 2). The calibration was completed 
183 by internal standardization. The linear calibration parameters were evaluated using the least 
184 squares regression method. Determination coefficient (R2), slope, and intercept were calculated, 
185 and several significance tests were performed to evaluate linearity, including Lack-of-Fit test, 
186 Analysis of Variance (ANOVA) test, Mandel's test, evaluations of the relative standard deviation of 
187 the slope (RSD slope test) and the residual plots, together with the analysis of the deviation from 
188 back-calculated concentrations. 
189 The tests were passed when the calculated values (Fexp) proved to lower than the corresponding 
190 critical value at α=0.05 significance level: Fcrit = 2.776 (n1 = 4 and n2 = 24 degrees of freedom) for 
191 the Lack-of-Fit test, Ftab = 3.842 (n1 = 1 and n2 = 28 degrees of freedom) for the ANOVA test, and 
192 Fcrit = 2.62 (n1 = 5 and n2 = 24 degrees of freedom) for the Mandel’s test. With respect to the 
193 RSDDS slope and back calculation tests, the adopted threshold values were 5.00% and 20%, 
194 respectively. The residual plot analysis turned out positive when a random pattern was observed, 
195 namely there was no recognizable trend of the residuals as a function of the concentrations.
196 The LOD values were estimated using the Hubaux and Vos approach [26]. Five independent 
197 calibration lines were prepared for all the target analytes and a significant level of 95% was 
198 selected at the corresponding number of degree of freedom. Then, LOD value was calculated by 
199 applying the Hubaux-Vos algorithms. LOQ was calculated as two times the LOD.
200 The calculated LOD and LOQ values were subsequently tested in experiments with blank urine 
201 samples spiked with analyte concentrations extremely close to the respective LOD and LOQ values, 
202 to confirm the estimation correctness.
203
204 2.4.3. Precision and accuracy
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205 For all analytes, intra-day precision (expressed as percent variation coefficient, CV%) and accuracy 
206 (expressed as bias%) were evaluated by analyzing ten blank urine samples spiked with the working 
207 solutions at low, medium and high calibration level (the same concentrations used for selectivity 
208 evaluation). Intra-assay precision was considered satisfactory when CV% values were below 25% 
209 for the low calibration level and below 15% for the other levels. Satisfactory accuracy was 
210 achieved when the experimentally determined average concentration lied within ±15% from the 
211 expected value. All results are reported in Table 3.
212
213 2.4.4. Carry-over
214 Carry-over was evaluated by injecting an alternate sequence of five blank urine samples spiked 
215 with all the analytes at concentrations higher than 5 ng/mL and five blank urine samples. To 
216 ensure the absence of any carry-over effect, S/N ratios had to be lower than 3 for each monitored 
217 transition.
218
219 2.4.5. Matrix effect and extraction recovery
220 The matrix effect was evaluated as the percentage ratio between the area (mean value from five 
221 replicates) obtained by adding the analyte to the matrix extract and the one determined in a blank 
222 deionized water solution spiked with the analyte at the same concentration after the extraction 
223 step. The percentage difference highlighted matrix suppression (values below 100%) or 
224 enhancement (values above 100%) [27]. Matrix effect was estimated at the first level of the 
225 calibration curves.
226 The extraction recovery represents the percentage of analyte extracted after sample workup from 
227 a blank urine sample originally spiked with a known concentration of target analytes. It was 
228 calculated as the ratio between the analyte area determined in the extracted samples (5 
229 replicates) and the one determined in blank samples (5 replicates) in which the analyte was added 
230 after the extraction step. Extraction recoveries were estimated at the three concentration levels 
231 cited above.
232
233 2.5. Real urine samples
234 In order to verify the complete analytical procedure on authentic specimens, real urine samples 
235 were collected from 60 compliant patients, who were subjected to pharmacological treatment 
236 with β2-agonists at San Luigi Gonzaga University Hospital. General information on the patients and 
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237 their treatment with β2-agonists is listed in Tables 4 and 5. Briefly, β2-agonists were administered 
238 using pressurized metered dose inhalers. The active ingredients were salbutamol (100 µg/puff), 
239 salbutamol/beclometasone (100 µg/puff), salmeterol/fluticasone (25 or 50 µg/puff), 
240 formoterol/budesonide (4.5 or 9 µg/puff), formoterol/beclometasone (6 µg/puff) and indacaterol 
241 (150 µg/puff). All analyses were routinary therapeutic controls executed for clinical purposes. 
242 However, the patients provided written informed consent before attending the study, and an 
243 anonymous code was attributed to each subject participating to the present study to respect 
244 privacy regulations.
245
246 3. Results and discussion
247 3.1. Method development
248 The optimized UHPLC-MS/MS method allowed the simultaneous determination of 24 β2-agonists 
249 in human urine. The whole chromatographic run, comprehensive of the time required for column 
250 re-equilibration before the following injection, was completed in less than 15 min. Retention times 
251 ranged between 2.70 min (cimaterol) and 8.84 min (salmeterol). Figure 2 shows the SRM 
252 chromatograms recorded from a blank urine spiked with all the analytes at 0.5 ng/mL.
253 The choice of the SPE procedure, that involved mixed-phase cartridges with both ion-exchange 
254 and lipophilic properties, was made after comparison of literature results. In particular, a very 
255 exhaustive comparative study of various sorbents types was made by Dos Ramos et al on bovine 
256 urine as the matrix, suggesting the use of mixed-phase sorbent as the one yielding the best results 
257 in β2-agonists recovery [28]. The present results confirm that optimal clean-up is observed by 
258 using mixed-phase SPE cartridges.
259
260 3.2. Validation results
261 3.2.1. Specificity and Selectivity
262 The SRM chromatographic profiles obtained from blank urine samples collected from 10 untreated 
263 subjects did not show the presence of any significant signal (S/N<3) at the relative retention time 
264 typical of all the studied compounds and ISs, indicating that the method is selective and no 
265 interfering substance is present in the biological matrices. 
266 The analytes were clearly identified in all the spiked samples, according to the criteria reported in 
267 the Decision 2002/657/EC, that were fully satisfied. 
268
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269 3.2.2. Linearity, LOD and LOQ
270 The linear matrix-matched calibration model was checked by analyzing five replicate blank urine 
271 samples spiked with the working solutions at six final concentrations. More in detail, two intervals 
272 were investigated for the analytes listed in Table 2, depending on the typical therapeutic dose of 
273 each β2-agonist and its expected concentration in urine: 0.03–2.5 ng/mL (0.03, 0.1, 0.25, 0.5, 1.0 
274 and 2.5 ng/mL) or 0.15–5.0 ng/mL (0.15, 0.25, 0.5, 1.0, 2.5 and 5.0 ng/mL). Quantitative data 
275 resulting from area counts were corrected using the respective IS signal areas. All the linear 
276 calibration parameters turned out adequate and the results, reported in Table 2, confirm the 
277 appropriateness of the linear model. Further confirmation of the calibrations linearity was 
278 obtained from the analysis of the residual plots, since a random residuals pattern along the 
279 concentration range was observed for all the analytes.
280 LODs were calculated by the Hubaux-Vos technique [26] and the experimental verification tests 
281 confirmed the correct estimation of LOD and LOQ. The Hubaux-Vos method is founded on rigorous 
282 statistical basis and should be preferred with respect to the LOD and LOQ estimation made from 
283 the S/N values of blank and spiked samples or the average signal and its standard deviation. In 
284 particular, the latter methods do not define the baseline position and amplitude from which the 
285 S/N value should be calculated, introducing a potential factor of bias related to the operator’s 
286 discretion. The LODs and LOQs values reported in Table 2 proved to be at least one order of 
287 magnitude lower than those recorded in our previous fast-GC-MS method [23]. This increase in 
288 sensitivity turned out to be particularly important for some analytes, i.e. salmeterol, commonly 
289 excreted at low concentration after administration.
290
291 3.2.3. Precision and accuracy
292 Intra-day data on precision and accuracy are reported in Table 3. The results show satisfactory 
293 repeatability, as the percent variation coefficient (CV%) is lower than 15% for all the spiked 
294 analytes at low, medium and high concentrations, with only five exceptions (16% for cimaterol, 
295 19% for ritodrine, 16% for ractopamine, 17% for mapenterol and 18% for salmeterol at the lowest 
296 calibration level). The accuracy is also satisfactory, as the percent bias (bias%) ranges from -4.7% 





301 The background chromatographic profiles of the main SRM transitions for each analyte, monitored 
302 during the analysis of blank urine injected after highly spiked samples, did not show the presence 
303 of any significant signal (i.e. the S/N value was always <3) at the retention times expected for the 
304 tested analytes, with the notable exception of procaterol that showed some carry-over effect in 
305 two runs out of five. It is recommended to inject a blank sample after the injection of the last point 
306 of the calibration curve and in general after any sample with high procaterol concentration.
307
308 3.2.5. Matrix effect and recovery
309 Recovery and matrix effect values are given in Table 3. In general, the results show satisfactory 
310 recovery values. The average extraction recovery is 100%: the minimum observed value is 80% for 
311 mapenterol at 0.03 ng/mL, while the maximum value equals 116% for fenoterol at 0.15 ng/mL. 
312 The average matrix effect is estimated around +1.2%: the highest negative effect is -33% for 
313 cimaterol, while the largest positive effect is +23% for clenbuterol. In conclusion, good extraction 
314 recoveries combined with acceptable matrix effect allowed the correct determination of all the 
315 target analytes. 
316
317 3.3. Method improvement
318 The present UHPLS-MS/MS method was developed to be used in the daily laboratory activity in place of the 
319 fast-GC-MS procedure previously employed [23]. The former method provided reasonable sensitivity and 
320 adequate instrumental processing time to meet the requirements (in terms of LOQ and sample throughput) 
321 of most routine determinations. However, it needed to be updated to include the newest β2-adreneregic 
322 receptor agonists, among which indacaterol, zilpaterol, isoxsuprine, and mabuterol, occasionally adopted in 
323 the clinical and veterinary practice or potentially abused. Moreover, the GC-MS method required a strong 
324 derivatization step under strictly controlled conditions, to reduce the polarity of most targeted analytes. 
325 For example, the derivatization with trimethylsilyltrifluoroacetamide introduced three TMS groups in 
326 salbutamol and formoterol and four TMS groups in salmeterol.
327 The new method is equally fast, does not require previous derivatization steps, and is validated for as many 
328 as 24 target β2-agonists, namely all those potentially requested to our laboratory for both clinical and 
329 doping purposes. The combination of electrospray ionization with tandem mass spectrometry, together 
330 with the addition of SPE purification of the extract, considerably improved the sensitivity with respect to 
331 the previous method [23]. On average, LOD values were decreased by 1-2 orders of magnitude for all the 
332 analytes included in both methods. Moreover, a few specificity problems observed in the GC-MS method 
333 had been eliminated. For example, the signal obtained from low formoterol concentrations in real samples 
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334 was barely detectable in the GC-SIM profile as a shoulder at the right side of an interfering peak, making 
335 the quantification highly problematic. In the present method, the use of SPE purification and MS/MS 
336 detection removed all interferences from SRM profiles, enhancing both specificity and sensitivity.
337
338 3.3.3.4. Real samples results
339 All four β2-agonists (formoterol, indacaterol, salbutamol and salmeterol) administered to the 
340 patients were detected in the real samples. A representative SRM profile for each analyte is 
341 reported in Figure 3, showing optimal chromatographic profiles at both high and low 
342 concentrations. The therapeutic, chronological, and analytical data for real clinical samples are 
343 reported in Table 4 (chronic therapy) and Table 5 (acute therapy).
344 3.3.1.3.4.1. Indacaterol
345 Indacaterol is a novel, long-acting inhaled β2-adreneregic receptor agonist intended for long-term, 
346 single daily dose, maintenance treatment in patients with COPD [29]. The long-lasting 
347 pharmacological activity of indacaterol is due to the presence of a long, lipophilic side-chain in the 
348 chemical structure that binds to an exo-site on adrenergic receptors [30]. The urine of a 66 years 
349 old woman was collected 24 hours after the last assumption of 150 µg of indacaterol and two 
350 weeks long therapy. The patient had been in therapy with salbutamol for 16 years, as needed, but 
351 with poor control of the disease. Then, salbutamol was substituted with indacaterol, which 
352 required single daily dose. The drug was found in urine at the concentration of 3.93 ng/mL (see 
353 Figure 3, line C). Salbutamol was still detected at the concentration of 42.1 ng/mL, 18 days after its 
354 replacement (reported below).
355
356 3.3.2.3.4.2. Salmeterol
357 Salmeterol is a long-acting selective β2-agonist used to control asthma in combination with inhaled 
358 steroid therapy. In contrast, salmeterol could be used as a monotherapy in COPD. Its 
359 concentration in urine after administration is very low, inasmuch as it is readily metabolized to α-
360 hydroxysalmeterol [31]. The urine samples from twelve patients in chronic therapy with variable 
361 doses and collecting intervals after administration were analyzed. The results, reported in Table 4, 
362 show that higher average salmeterol concentration is detected from patients with longer 
363 therapeutic periods (more than 6 months), possibly because of some accumulation effect. For 
364 example, different salmeterol concentrations were detected from patients 012, 039 and 043, i.e. 
365 women of a similar age under the same therapy conditions and sampling interval. The 
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370 Formoterol is a potent long-acting β-agonist, typically applied by means of a metered dose inhaler. 
371 It shows rapid action offset, which is exploited in asthma - in association with inhaled steroid - not 
372 only for disease control but also as a reliever. In COPD, formoterol can be used in monotherapy. At 
373 high doses, it may also act as an anabolic agent, increase the heart rate, and produce excitement. 
374 Hence, formoterol might potentially be misused in sports for its stimulatory effect and possible 
375 anabolic action, although most studies on the effects of inhaled β-agonists did not show any 
376 improvement in the elite athletes performance [32].
377 Urine samples from patients who used formoterol in both acute and chronic therapy were 
378 analyzed. In chronic patients, the detected urinary concentrations of formoterol were scattered, 
379 varying in the range between fractions and units of ppb, with two notable exception of higher 
380 levels (patients 030 and 046). According to the data reported in literature, formoterol is excreted 
381 in urine either as phase I (O-demethylation of the methoxyphenyl group and deformylation) or 
382 phase II metabolites (glucuronidation mainly at the phenolic position, but a benzyl glucuronide is 
383 also formed) [33], accompanied by a large percentage of unmodified drug [34]. No differences 
384 were observed between patients in therapy from more or less than sixth months and no clear 
385 dependence from the dosage was detected.
386 In patients under acute therapy, all the detected concentrations were lower than 0.702.0 ng/mL 
387 (0.50±0.07 ng/mL). Urine samples collected too early (patient 015) or too late (patients 001-003-
388 049) with respect to the administration lead to low or undetectable drug levels, although in 
389 patient 036 formoterol was still detected 48 hour after administration. 
390
391 3.3.4.3.4.4. Salbutamol 
392 Salbutamol is a widely prescribed β2-agonist for relieving bronchospasm in patients with asthma 
393 and COPD [35]. The list of prohibited substances in sports published by the WADA specifies that 
394 the use of salbutamol is only permitted by inhalation. Administration by the oral or parenteral 
395 route or the administration of very large inhaled doses are forbidden due to an strong adrenergic 
396 stimulatory effect and an anabolic-like effect. In contrast, administration of therapeutic inhaled 
397 doses have no ergogenic effect [36]. 
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398 The urine samples of 10 patients to whom salbutamol was administered in acute therapy were 
399 analyzed (see Table 5). Although relatively high concentrations of salbutamol were always 
400 measured, it is evident that the urinary concentration of salbutamol decreased from hundreds to 
401 tens of ppb ng/mL after 12 or more hours from the assumption (patients 026 and 027). The single 
402 recorded exception (patient 008) showing low salbutamol urinary concentration, actually received 
403 a small dosage of salbutamol. The persistence and possible accumulation of the drug in the body 
404 was supported by the analysis of an urine sample from a patient chronically treated with 
405 salbutamol (50+50 µg/day) for the last 16 years: 18 days after the therapy suspension, salbutamol 
406 was still present at the relatively high concentration of 42 ppb ng/mL (Patient 006 in Table 4). Less 
407 pronounced effect was recorded for a 38-years old male subject, who was in therapy since one 
408 year with 200 µg/day salbutamol: after 3 hours from administration, its urinary concentration was 
409 57±7 ng/mL. 
410
411 4. Conclusions
412 The UHPLC-MS/MS method developed and validated for the simultaneous quantitative 
413 determination of 24 β-agonists in human urine proved adequate to measure the real 
414 concentration of these analytes in real samples of patients with asthma or COPD. The method 
415 proved simple, accurate and highly sensitive, allowing the simultaneous detection of all 
416 compounds within a short run time. In comparison with the method we previously used [23], more 
417 analytes (24 instead of 15) and increased sensitivity (at least one order of magnitude) were gained. 
418 The results on real samples allowed us to directly verify that salbutamol and salmeterol tend to 
419 accumulate in the body, when the therapy is administered for long periods of time, even if the 
420 excretion appears to vary significantly from one patient to another. Moreover, very low 
421 concentrations were detected after formoterol assumption, even when the drug was administered 
422 in high dosage to control acute asthma episodes.
423
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β2-agonist compounds R1 R2 R3 R4 R5 R6 R7 R8
Bambuterol H N(CH3)2COO H N(CH3)2COO H CH3 CH3 CH3
Bromchlorbuterol H Cl NH2 Br H CH3 CH3 CH3
Bromobuterol H Br NH2 Br H CH3 CH3 CH3
Cimaterol H C≡N NH2 H H H CH3 CH3
Cimbuterol H C≡N NH2 H H CH3 CH3 CH3
Clenbuterol H Cl NH2 Cl H CH3 CH3 CH3
Clencyclohexerol H Cl NH2 Cl H H OH
Clenpenterol H Cl NH2 Cl H C2H5 CH3 CH3
Clenproperol H Cl NH2 Cl H H CH3 CH3
Fenoterol H OH H OH H CH3 OHCH2 H
Formoterol H NH-COH OH H H CH3 OCH3CH2 H
Hydroxymethylclenbuterol H Cl NH2 Cl H CH2OH CH3 CH3
Isoxsuprine H H OH H CH3 CH3 OCH2 H
Mabuterol H CF3 NH2 Cl H CH3 CH3 CH3
Mapenterol H CF3 NH2 Cl H C2H5 CH3 CH3
Ractopamine H H OH H H CH3
CH2 CH2 OH H
Ritodrine H H OH H CH3 H OHCH2 H
Salbutamol H CH2OH OH H H CH3 CH3 CH3
Salmeterol H CH2OH OH H H H -(CH2)6O(CH2)4Ph H
Terbutaline H OH H OH H CH3 CH3 CH3























Figure 1. Chemical structures of β2-agonists considered in this study.
Figure 2. SRM chromatograms of a blank urine sample spiked at 0.500 ng/mL for all the analytes. In black is 
reported the quantifier fragment and in red the qualifier fragment.  
Figure 3. SRM chromatogram of four real samples positive to A) salbutamol at 171±21 ng/mL (patient 003), 
B) formoterol at 0.650.646±0.090 ng/mL (patient 002), C) indacaterol at 3.93±0.32 ng/mL (patient 006) and 
D) salmeterol at 0.374±0.048 ng/mL (patient 010). In black is reported the quantifier fragment and in red 
the qualifier fragment.  
Table 1. SRM transitions and corresponding potentials for the target compounds and internal standards detection.




CE (V) CXP (V) Qualifier fragment CE (V) CXP (V)
Cimaterolb 2.70 219.9 33 10 202.1 14 15 143.3 32 15
Terbutalinea 3.23 226.2 30 7 152.1 27 17 125.2 36 12
Zilpaterola 3.43 262.1 28 10 185.2 30 9 244.3 16 21
Salbutamola 3.54 240.2 30 7 148.0 25 7 166.1 18 7
Cimbuterolb 4.06 234.2 43 7 160.0 21 7 143.0 35 10
Fenoterola 4.33 304.3 100 6 135.1 27 10 107.2 49 8
Procaterolb 4.36 291.2 49 10 273.2 21 25 214.1 33 20
Ritodrinea 4.49 288.1 50 8 150.0 26 10 121.1 29 12
Clencicloexerolb 4.79 319.0 42 10 203.0 29 8 132.1 45 8
Hydroxymethylclenbuterolb 5.09 293.0 40 10 203.2 26 13 132.0 41 13
Clenproperolb 5.14 263.0 45 8 203.1 27 8 188.1 27 8
Ractopaminea 5.43 302.2 40 11 164.1 24 14 136.1 33 10
Clenbuterolb 5.76 277.0 40 10 203.1 27 20 132.1 42 16
Formoterolc 5.95 345.2 25 9 149.0 25 10 121.1 48 11
Bromchlorbuterolb 5.98 321.0 33 10 246.9 25 10 302.6 26 10
Tulobuterolb 6.15 228.1 50 10 117.9 33 8 154.0 26 11
Bromobuterolb 6.23 367.0 30 10 293.1 25 13 212.2 42 13
Mabuterolb 6.30 311.1 35 10 236.9 23 13 217.1 36 13
Isoxsuprinea 6.39 302.1 42 10 284.1 20 15 150.3 31 15
Clenpenterolb 6.39 290.9 43 10 203.0 22 15 132.1 38 15
Bambuterola 6.61 368.2 43 10 294.0 28 8 212.2 20 10
Mapenterolb 6.88 325.0 40 10 237.2 22 15 217.2 36 15
Indacaterola 8.27 393.2 64 10 173.1 33 10 117.0 63 10
Salmeterold 8.84 416.3 75 9 398.2 22 11 380.2 27 11
Salbutamol D3a 3.52 243.2 38 10 151.0 26 15 - - -
Clenbuterol D6b 5.73 283.0 40 10 203.0 18 15 - - -
Formoterol 13C D3c 5.92 349.1 32 10 153.1 27 9 - - -
Salmeterol D3d 8.83 419.2 83 12 401.2 22 11 - - -
DP: Declustering Potential;   EP: Entrance Potential;   CE: Collision Energy;   CXP: Cell Exit Potential
Table 2. Calibration interval, squared correlation coefficient, LODs and LOQs values, Lack of Fit’s, ANOVA, Mandel’s, RDS slope and Back calculation test 
results for all analytes.
aCalibration levels (ng/mL) = 0.15 – 0.25 – 0.5 – 1.0 – 2.5 – 5.0 
bCalibration levels (ng/mL) = 0.03 – 0.1 – 0.25 – 0.5 – 1.0 – 2.5
Lack of fit’s test – Fcrit = 2.776 (n1 = 4 and n2 = 24 degrees of freedom)
ANOVA – Ftab = 3.842 (n1 = 1 and n2 = 28 degrees of freedom)
Mandel’s test -  Fcrit = 2.62 (n1 = 5 and n2 = 24 degrees of freedom)























Cimaterol 0.15-5.0 0.9983 0.0329 0.0586 0.24 0.494 1.34 2.98 6.07
Terbutaline 0.15-5.0 0.9969 0.0439 0.0878 0.67 0.707 1.47 2.85 10.1
Zilpaterol 0.15-5.0 0.9989 0.023 0.0546 0.16 0.415 1.23 2.63 3.90
Salbutamol 0.15-5.0 0.9998 0.011 0.022 0.04 0.285 1.45 2.00 1.88
Cimbuterol 0.03-2.5 0.9994 0.0109 0.0218 0.07 0.502 1.31 3.35 5.73
Fenoterol 0.15-5.0 0.9959 0.045 0.089 0.34 0.673 1.85 4.46 7.03
Procaterol 0.15-5.0 0.9994 0.0218 0.04035 0.08 0.664 1.40 3.72 5.25
Ritodrine 0.15-5.0 0.9955 0.0547 0.094 0.58 0.467 2.48 3.03 13.3
Clencicloexerol 0.15-5.0 0.9999 0.0071 0.014 0.03 0.127 1.04 1.11 2.84
Hydroxymethylclenbuterol 0.15-5.0 0.9999 0.0071 0.014 0.04 0.302 1.26 1.47 1.83
Clenproperol 0.15-5.0 0.9993 0.0218 0.0364 0.16 0.376 2.31 1.98 4.37
Ractopamine 0.15-5.0 0.9995 0.0216 0.031 0.07 0.794 1.30 3.89 1.89
Clenbuterol 0.15-5.0 0.9990 0.022 0.044 0.10 0.926 1.32 4.87 5.18
Formoterol 0.15-5.0 0.9998 0.010 0.021 0.06 0.081 1.09 0.84 2.38
Bromchlorbuterol 0.15-5.0 0.9993 0.0182 0.00436 0.09 0.510 1.59 3.01 5.47
Tulobuterol 0.03-2.5 0.9990 0.011 0.022 0.14 0.593 1.20 3.23 6.73
Bromobuterol 0.03-2.5 0.9979 0.0216 0.032 0.34 0.886 1.02 3.69 11.4
Mabuterol 0.15-5.0 0.9998 0.011 0.021 0.03 0.474 1.00 3.17 2.45
Isoxsuprine 0.15-5.0 0.9990 0.022 0.043 0.16 0.334 1.99 2.26 3.26
Clenpenterol 0.15-5.0 0.9990 0.022 0.045 0.16 0.443 1.97 2.64 3.99
Bambuterol 0.03-2.5 0.9992 0.010 0.020 0.18 0.373 2.17 1.99 6.46
Mapenterol 0.03-2.5 0.9977 0.0217 0.034 0.34 0.465 2.00 2.80 9.56
Indacaterol 0.15-5.0 0.9990 0.023 0.0465 0.18 0.572 1.73 2.87 2.85
Salmeterol 0.03-2.5 0.9998 0.0051 0.010 0.05 0.235 1.61 1.58 4.88
Back calculation test - % threshold = 20%
Table 3. Intra-day precision (CV%), accuracy (bias%), matrix effect and extraction recovery for all the analytes tested.
























Cimaterol 0.15 16 +5.5 0.50 9.7 +0.1 2.5 5.1 +1.5 -33 108 100 101
Terbutaline 0.15 12 +1.3 0.50 7.3 -1.2 2.5 2.5 +1.6 +0.05 97 100 99
Zilpaterol 0.15 9.4 +1.2 0.50 8.3 +1.6 2.5 4.8 +2.0 -1.7 107 110 96
Salbutamol 0.15 7.1 -4.7 0.50 4.5 -1.4 2.5 4.0 +2.3 +5.7 91 94 100
Cimbuterol 0.03 7.5 +6.7 0.25 4.5 +3.5 1.0 4.5 +2.4 +5.7 97 95 97
Fenoterol 0.15 12 +8.4 0.50 5.2 -1.8 2.5 3.7 +2.4 -2.7 116 103 103
Procaterol 0.15 13 +3.2 0.50 3.7 -3.0 2.5 1.1 +0.4 +4.2 98 88 102
Ritodrine 0.15 19 +7.4 0.50 4.8 -0.9 2.5 3.4 +0.6 -19.3 95 102 97
Clencicloexerol 0.15 5.0 +4.6 0.50 4.3 +0.6 2.5 3.3 +0.3 -8.0 113 111 95
Hydroxymethylclenbuterol 0.15 11 -0.9 0.50 3.4 -3.1 2.5 0.3 +0.02 -1.9 98 107 96
Clenproperol 0.15 11 -0.7 0.50 7.0 +2.6 2.5 0.8 +0.2 +12 89 100 96
Ractopamine 0.15 16 +15 0.50 8.8 +1.8 2.5 1.6 -0.6 -1.2 106 98 100
Clenbuterol 0.15 9.9 +9.8 0.50 8.4 +1.0 2.5 7.1 +1.8 +23 98 99 98
Formoterol 0.15 10 +2.8 0.50 6.0 +1.1 2.5 2.4 -0.5 +17 102 105 98
Bromchlorbuterol 0.15 8.0 -0.2 0.50 1.5 +0.3 2.5 2.8 +0.8 +2.6 99 85 100
Tulobuterol 0.03 11 +10 0.25 3.2 -1.0 1.0 5.0 -0.4 +9.2 110 89 98
Bromobuterol 0.03 2.3 +3.4 0.25 3.4 +0.3 1.0 2.6 +0.5 -3.7 102 92 105
Mabuterol 0.15 10 +14 0.50 7.2 +0.1 2.5 7.3 -2.5 +16 101 102 99
Isoxsuprine 0.15 11 +1.8 0.50 2.5 -0.4 2.5 0.6 -0.1 -2.5 99 96 101
Clenpenterol 0.15 1.9 +0.4 0.50 3.8 -0.6 2.5 3.2 +1.3 -4.2 102 96 98
Bambuterol 0.03 3.5 +6.9 0.25 4.7 +3.2 1.0 2.1 +0.5 +5.0 104 96 98
Mapenterol 0.03 17 +13 0.25 2.8 +2.1 1.0 2.8 +0.3 +8.7 80 94 105
Indacaterol 0.15 13 +4.5 0.50 5.3 +0.8 2.5 1.6 +0.4 +1.2 100 110 106
Salmeterol 0.03 18 -0.4 0.25 2.9 +3.7 1.0 0.5 -0.4 -3.8 110 88 99
Table 4. Patients under chronic therapy. General features, treatment information, and β-agonists 
concentration determined in urine.
CHRONIC THERAPY
β-agonist Patient Sex Age Time in therapy (months)
Time from last 
administration (h) Dose (µg)
Urine concentration 
(ng/mL)
010 F 50 36 1 25+25 0.37
012 F 72 2 3 50+50 0.02
039 F 64 6 3 50+50 0.08
043 F 65 36 3 50+50 0.38
044 F 39 3 3 25+25 0.07
050 M 56 60 3 25+25 0.55
017 F 64 10 5 50+50 0.22
035 M 43 4 5 50+50 0.11
058 F 28 2 6 50+50 ND
022 M 81 3 7,5 50+50 0.16
041 F 59 72 8 50+50 0.16
Salmeterol
040 M 38 24 48 50+50 ND
Indacaterol 006 F 66 0.5 24 150 3.93
054 F 30 2 0.5 12+12 4.05
004 F 60 1 1 6+6 1.20
016 F 83 0.25 1.5 6 0.50
046 F 27 120 2 12+12 41.2
029 M 53 15 3 12+12 1.78
031 F  3 3 6+6 1.99
037 M 23 60 3 4,5+4,5 0.81
057 F 47 3 3 12+12 1.16
020 F 46 48 4 12+12 0.14
030 F 48 0.25 4 12+6 15.9
056 M 20 1 4 4,5+4,5 0.63
014 F 34 3 5 6+6 0.77
019 F 49 1 5 4,5 + 4,5 0.30
028 M 54 2.5 5 9 2.00
005 M 75 0.25 6 12+12+12 0.62
032 F 45 2 6 6+6 0.46
038 F 49 60 6 4,5 + 4,5 2.69
055 F 54 36 7 6+6 2.20
011 M 56 72 8 4,5 0.23
042 F 65 132 8 4,5+4,5 0.30
021 F 70 5 14 6+6 1.20
023 F 26 1.5 14 6+6 0.05
013 F 30 2 14 12 0.14
033 M 16 10 15 12+12 0.88
045 M 29 8 15 6+6 ND
018 F 54 36 17 6+6 ND
034 F 41 12 17 4,5 + 4,5 0.10
025 F 43 0.75 20 12+12 0.12
048 F 34 12 30 6 1.88
047 F 62 1.5 48 6 ND
Formoterol
009 F 13 1 52 6+6 < LOQ
059 M 38 12 3 200 57Salbutamol
006 F 66 16 years 18 days 50+50 42.1
*ND = not detected
Table 5. Patients under acute therapy. General features, treatment information, and β-agonists 
concentration determined in urine.
ACUTE THERAPY
β-agonist Patient Sex Age Time in therapy (h) Dose (µg) Urine concentration (ng/mL)
015 M 30 0.25 4.5 <LOQ
007 F 38 0.5 5+5 2.0
002 M 61 4 200 0.65
053 F 52 6 6 0.41
027 M 33 8 18 1.3
049 M 29 16 9 ND
001 F 33 17.5 4.5 <LOQ
003 M 33 18.5 4.5 <LOQ
Formoterol
036 F 24 48 4.5+4.5 0.09
051 F 48 0.5 400 171
052 F 53 1 400 926
060 M 34 1 400 103
003 M 33 1.5 300 171
008 F 70 2 200 1.20
013 F 30 2 400 138
024 M 21 2 400 406
040 M 38 3 400 295
027 M 33 12 1312 41.4
Salbutamol
026 F 29 15 200 12.8
* ND = not detected
